Month: June 2022
Excerpt from the Press Release: CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) announced that it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., May 24, 2022 /PRNewswire/ — OptraSCAN®, the leading end-to-end digital pathology solution provider, announced its digital pathology scanner OS-SiA has been granted US patent – No 2020/0334814 A1 by the United States Patent and Trademark Office. OS-SiA has inbuilt intelligence to scan, index and analyze pathological samples…
Read More
Excerpt from the Press Release: SANTA CLARA, Calif., May 24, 2022 /PRNewswire/ — Invenio Imaging, the leader in intraoperative fresh tissue imaging, announced today the CE Mark for the NIO Glioma Reveal image analysis module. NIO Glioma Reveal is based on deep learning and allows neurosurgeons to identify areas of cancer infiltration in patients undergoing primary…
Read More Open-Label Trial in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101 (taladegib)…
Read More
Meet with Christopher Kata, Director of Sales & Marketing and the TrialStat Team on June 20th – 22nd! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 27th – July 1st 2021Where: McCormick Place 2301 S King Dr, Chicago, IL 60616, United StatesRegistration: DIA Global Annual Meeting 2022 It’s hard to believe an entire…
Read More
Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–May 24, 2022– DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it is sponsoring The Sun Bus, a community service provided by the Colorado Melanoma Foundation in partnership with Epiphany Dermatology, to…
Read More
Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule Excerpt from the Press Release: SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters…
Read More
– Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma – Excerpt from the Press Release: ROTTERDAM, Netherlands and NEWTON, Mass., May 25, 2022 /PRNewswire/ — The European Myeloma Network (EMN), an international collaborative network of expertise centers for…
Read More
Automated and Easily Scalable Swab-Based Workflow Supports Increased Sample Throughput and Processing Consistency Excerpt from the Press Release: WALTHAM, Mass. & WATERTOWN, Mass.–(BUSINESS WIRE)–Rhinostics Inc. and Nexus Medical Labs recently received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test enabling unsupervised self-collection. The test, based on…
Read More
Expanding etavopivat development in 2022 with Phase II trial exploring transfusion burden across sickle cell disease (SCD), thalassemia and myelodysplastic syndromes (MDS) Phase 1 trial of FT-7051 in mCRPC proceeding with predicted efficacious dose range under evaluation and exploring alternative dosing schedule FT-3171 (USP1 inhibitor) introduced targeting BRCA mutant tumors with investigational new drug…
Read More